Bone Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Ameliorated Lipopolysaccharide-Induced Lung Injury Via the miR-21-5p/PCSK6 Pathway

Figure 4

BMSC-sEVs ameliorated LPS-induced BEAS-2B cell injury by suppressing PCSK6 expression. (a–c) BMSC-sEVs inhibited the expression of PCSK6 in LPS-treated BEAS-2B in a dose-dependent manner. vs. control ^!, ^!!, and ^!!! vs. LPS treatment group. (d) BMSC-derived sEVs ameliorated LPS-induced proliferation inhibition, but the effects were weakened by PCSK6 overexpression. (e) BMSC-derived sEVs reduced FITC-dextran of BEAS-2B cells exposed to LPS, but the effects were weakened by PCSK6 overexpression. (f) BMSC-derived sEVs enhanced the TEER value of BEAS-2B cells exposed to LPS, but the effects were weakened by PCSK6 overexpression. (g, h) BMSC-derived sEVs reduced TNF-α and IL-1β production in BEAS-2B cells exposed to LPS, but the effects were weakened by PCSK6 overexpression. vs. vehicle. ^!!! vs. the LPS treatment group. ^##, and ^### vs. oeNC + LPS + BMSC-sEVs.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)